V体育2025版 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2011 Jul 14;118(2):282-8.
doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Claudio G Brunstein  1 , Ephraim J Fuchs, Shelly L Carter, Chatchada Karanes, Luciano J Costa, Juan Wu, Steven M Devine, John R Wingard, Omar S Aljitawi, Corey S Cutler, Madan H Jagasia, Karen K Ballen, Mary Eapen, Paul V O'Donnell; Blood and Marrow Transplant Clinical Trials Network
Collaborators, Affiliations
Clinical Trial

"VSports在线直播" Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Claudio G Brunstein et al. Blood. .

Abstract

The Blood and Marrow Transplant Clinical Trials Network conducted 2 parallel multicenter phase 2 trials for individuals with leukemia or lymphoma and no suitable related donor. Reduced intensity conditioning (RIC) was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow) transplantation. For both trials, the transplantation conditioning regimen incorporated cyclophosphamide, fludarabine, and 200 cGy of total body irradiation. The 1-year probabilities of overall and progression-free survival were 54% and 46%, respectively, after dUCB transplantation (n = 50) and 62% and 48%, respectively, after Haplo-marrow transplantation (n = 50). The day +56 cumulative incidence of neutrophil recovery was 94% after dUCB and 96% after Haplo-marrow transplantation. The 100-day cumulative incidence of grade II-IV acute GVHD was 40% after dUCB and 32% after Haplo-marrow transplantation. The 1-year cumulative incidences of nonrelapse mortality and relapse after dUCB transplantation were 24% and 31%, respectively, with corresponding results of 7% and 45%, respectively, after Haplo-marrow transplantation. These multicenter studies confirm the utility of dUCB and Haplo-marrow as alternative donor sources and set the stage for a multicenter randomized clinical trial to assess the relative efficacy of these 2 strategies VSports手机版. The trials are registered at www. clinicaltrials. gov under NCT00864227 (BMT CTN 0604) and NCT00849147 (BMT CTN 0603). .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment plans. Treatment schemas for (A) RIC and dUCB transplantation and (B) haplo-marrow transplantation.
Figure 2
Figure 2
Hematopoietic recovery. Neutrophil (A,C) and platelet recovery (B,D) after RIC and dUCB (A-B) or Haplo-marrow (C-D) transplantation.
Figure 3
Figure 3
GVHD. Cumulative incidences of acute (A,C) and chronic (B,D) GVHC after RIC with either dUCB transplantation (A-B) or Haplo-marrow transplantation (C-D).
Figure 4
Figure 4
Long-term outcomes. Relapse and NRM (A,C), OS, and event-free survival (B,D) after RIC and either dUCB (A-B) or Haplo-marrow transplantation (C-D).
See this image and copyright information in PMC

"VSports app下载" Comment in

References

    1. Giralt S, Logan B, Rizzo D, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007;13(7):844–852. - PubMed
    1. Platzbecker U, Thiede C, Fussel M, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006;20(4):707–714. - PubMed (VSports在线直播)
    1. Popat U, Heslop HE, Durett A, et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006;37(6):547–552. - PubMed
    1. Grigg AP, Gibson J, Bardy PG, et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant. 2007;13(5):560–567. - V体育安卓版 - PubMed
    1. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine andmelphalan. Biol Blood Marrow Transplant. 2007;13(4):454–462. - PMC (VSports app下载) - PubMed

VSports注册入口 - MeSH terms

Associated data